1. X
  2. Szi Kay Leung
Log inSign up
Szi Kay Leung
56 posts
Szi Kay Leung profile banner
user avatar

Szi Kay Leung

@SKayLeung
Post doc - University of Exeter - Functional Genomics of Alzheimer's disease ๐Ÿ‘ฉโ€๐Ÿ”ฌ
Joined October 2017
125
Following
93
Followers
RepliesRepliesMediaMedia
  • user avatar
    Szi Kay Leung
    @SKayLeung
    Aug 5, 2024
    ๐Ÿ“œ Thrilled to announce that this is now published on Nature Communications, where we report similar #isoform diversity & #splicing patterns in mice with AD neuropathology and human AD brain using #ONT nanopore sequencing! doi.org/10.1038/s41467โ€ฆ
    user avatar
    Szi Kay Leung
    @SKayLeung
    Sep 29, 2023
    Thrilled to share our latest preprint on characterizing isoform diversity and splicing patterns in an AD mouse model using targeted long read-sequencing. And showcasing FICLE for the first time! biorxiv.org/cgi/content/shโ€ฆโ€ฆ
  • user avatar
    Szi Kay Leung
    @SKayLeung
    Sep 29, 2023
    Thrilled to share our latest preprint on characterizing isoform diversity and splicing patterns in an AD mouse model using targeted long read-sequencing. And showcasing FICLE for the first time! biorxiv.org/cgi/content/shโ€ฆโ€ฆ
  • user avatar
    Szi Kay Leung
    @SKayLeung
    Nov 16, 2021
    Our paper on characterisation of the isoform diversity in the human and mouse cortex is out and available as resource!
    user avatar
    Jonathan Mill
    @PsyEpigenetics
    Nov 16, 2021
    New paper led by @SKayLeung and @aaron_r_j - Full-length transcript sequencing of human and mouse cortex identifies widespread isoform diversity and alternative splicing. cell.com/cell-reports/fโ€ฆ
  • user avatar
    Szi Kay Leung
    @SKayLeung
    Jun 10, 2019
    Please Support! All pledges, big or small, can make an impact The Old Bath Community House spacehive.com/the-old-bath-cโ€ฆ

Log in or sign up for X

See whatโ€™s happening and join the conversation

Continue with phone
or
Log in with username or email
TermsยทPrivacyยทCookiesยทAccessibilityยทAds Infoยทยฉ 2026 X Corp.